Landsdale, PA (PRWEB) July 09, 2011
JDP Therapeutics Inc., a privately held specialty pharmaceutical company, today announced positive results for Phase I clinical study of its lead candidate JDP-205, a novel treatment for allergic reactions being developed by JDP. JDP-205 injection was also well tolerated in the clinic. The study was a randomized, single-center, single-dose, four-way crossover pivotal study to evaluate JDP-205 Injection in human volunteers on its pharmacokinetics, safety and tolerability.
“These results demonstrate that JDP’s proprietary technology can safely provide therapeutic drug levels very quickly without having significant adverse events, which presents a superior alternative to the current therapy for patients experiencing allergic attacks. The success of this study positions JDP into Phase II clinical trials smoothly and efficiently”, said Jie Du, Ph.D. President and CEO of JDP Therapeutics.
JDP-205 is a proprietary product being developed for the treatment of allergic reactions for the hospital market. A survey of 110 physicians revealed that 86% of responding doctors had indicated readiness to use JDP-205 when it is approved by the FDA. A second independent study with in-depth clinician interviews confirmed the findings.
Allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates but with very limited selections of medications. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in over 55 years.
About JDP Therapeutics Inc.
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.
JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.
For further information, please call 215-661-8557 or email info(at)jdptherapeutics(dot)com
# # #
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP’s product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP’s ability to fund such efforts with or without partners, and other risks.